Access to Cancer Testing and Treatment

In Canada, the Access to Cancer Testing and Treatment program provides high quality cancer genomic testing to patients with metastatic or recurrent lung cancer. Imagia Canexia Health has expanded geographic access to this testing program which can help oncologists direct therapy selection and clinical trial options. The test is currently offered at no cost to lung cancer patients in Canada and breast cancer patients in Quebec.

Learn more about Project ACTT

FAQs for Providers

Stay Connected

Don’t miss out on news, webinars, and other resources from Imagia Canexia Health. Subscribe to our mailing list to stay up to date on the latest. You can opt-out at any time.

Our Solutions

Plasma Follow It®

Imagia Canexia Health’s Follow It panel detects mutations in plasma. Plasma profiling (a type of liquid biopsy) can be used to help tailor treatment, monitor cancer progression, or detect treatment resistance.

Learn About Follow It

Tissue

Imagia Canexia Health’s Find It & Fusions panels detect mutations and gene fusion events in solid tumor tissue. Tissue profiling can be used to help inform treatment decisions or predict progression of cancer based on somatic mutations found in the tumor.

Learn About Tissue Assays

Canexia Informatics Platform

Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.

Learn About Our Reports

We’d like to hear from you

If you think Canexia’s solution might be appropriate for your patients and organization, please contact us for more information.

Contact Us